- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Immunovia AB: Immunovia announces final terms of rights issue | 52 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 28.09. | Immunovia AB: Immunovia carries out a rights issue of units of approximately SEK 63 million | 218 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 06.08. | Immunovia AB Q2 Loss Narrows | 1 | RTTNews | ||
| 06.08. | Immunovia AB: Immunovia Publishes Interim Report for April-June 2026 | 263 | GlobeNewswire (Europe) | Highlights April-June 2026Net sales and operating results for Q2 2026 in line with expectations: Net sales of 381 KSEK (90) for the period were comprised primarily of revenue from PancreaSure tests... ► Artikel lesen | |
| 13.05. | Immunovia AB: Bulletin From The Annual General Meeting On 13 May 2026 In Immunovia AB (publ) | 321 | GlobeNewswire (Europe) | Today, on 13 May 2026, the annual general meeting of Immunovia AB (publ) was held. A summary of the adopted resolutions follows below.
Resolution on the adoption of the accounts and allocation of resultThe... ► Artikel lesen | |
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 07.05. | Immunovia AB: Immunovia Publishes Interim Report for January-March 2026 | 435 | GlobeNewswire (Europe) | Highlights January-March 2026Net sales and operating results for Q1 2026 in line with expectations: Net sales of 374 KSEK (139) for the period included royalties and revenues from PancreaSure tests.... ► Artikel lesen | |
| 24.02. | Immunovia AB: Immunovia Publishes Full Year Report for 2025 | 732 | GlobeNewswire (Europe) | Highlights October-December 2025Net sales and operating results for Q4 2025 in line with expectations: Net sales of 354 KSEK for the period (455) largely reflected royalty revenue. Operating loss was... ► Artikel lesen | |
| 20.01. | Immunovia AB: The Board of Directors of Immunovia withdraws proposal for reverse share split and cancels Extraordinary General Meeting | 245 | GlobeNewswire (Europe) | Following discussions with major shareholders, the Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has decided to withdraw the proposal for a reverse share split and the Extraordinary... ► Artikel lesen | |
| 19.01. | Immunovia AB: Immunovia receives state regulatory approval for PancreaSure in California and initiates commercial rollout | 372 | GlobeNewswire (Europe) | Immunovia AB (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, today announced that it has received regulatory approval for its PancreaSure test in California, US, enabling commercial... ► Artikel lesen | |
| 17.12.25 | Immunovia AB: The Board of Directors of Immunovia proposes a reverse share split | 906 | GlobeNewswire (Europe) | The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") proposes that an Extraordinary General Meeting on 22 January 2026 resolves to carry out a reverse share split, in the ratio... ► Artikel lesen | |
| 26.11.25 | Immunovia AB: Immunovia receives final Medicare payment rate for PancreaSure test | 484 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a national payment... ► Artikel lesen | |
| 26.11.25 | Immunovia AB: Immunovia Publishes Interim Report for July-September 2025 | 500 | GlobeNewswire (Europe) | Highlights July-September 2025Net sales and operating loss for Q3 2025 in line with expectations: Net sales of 101 KSEK for the period (235) largely reflected royalty revenue. Operating loss was 25.5... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HIMS & HERS HEALTH | 26,020 | -0,46 % | Novo Nordisk, Eli Lilly oder Hims & Hers: Welche Abnehmspritzen-Aktie im Trend-Check vorne liegt - Jetzt lesen! | ||
| BECTON DICKINSON | 177,90 | +1,69 % | BD (Becton, Dickinson and Company): BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results | Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing... ► Artikel lesen | |
| RYMAN HEALTHCARE | 0,793 | -1,67 % | XFRA RH7: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| WELLBEING DIGITAL SCIENCES | 0,007 | -100,00 % | KGK Science Receives Growth Investment Led By Maxim Partners | ||
| NIAGEN BIOSCIENCE | 2,280 | 0,00 % | GetFeatured: Prime IV Hydration & Wellness Toco Hills Marks First Year in Atlanta, Highlights NAD+ IV Therapy and Niagen Options | Prime IV Hydration & Wellness (Toco Hills, GA) marks one year of serving Atlanta. The anniversary recognizes its first year of operations and highlights its NAD+ IV Therapy and Niagen(R) options. ... ► Artikel lesen | |
| SIENNA SENIOR LIVING | 12,900 | 0,00 % | Dividendenbekanntmachungen (15.10.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,63 USD 0,5648 EUR ABBOTT LABORATORIES CDR CA0028221046 0,1096 CAD 0,069 EUR ABBVIE INC US00287Y1091 1... ► Artikel lesen | |
| MICROPORT SCIENTIFIC | 0,688 | -100,00 % | XFRA MSK: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMICRP.SCIEN.REGS... ► Artikel lesen | |
| EXTENDICARE | 16,600 | 0,00 % | Extendicare declares CAD 0.0441 dividend | ||
| VERADIGM | 7,350 | -100,00 % | Veradigm Inc. - 8-K, Current Report | ||
| NATIONAL HEALTHCARE CORPORATION | 190,00 | 0,00 % | Dividendenbekanntmachungen (30.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1763 EUR ADVANCED FLOWER CAPITAL INC US00109K1051 0,05 USD 0,044 EUR AGNC INVESTMENT... ► Artikel lesen | |
| UNIPHAR | 4,015 | 0,00 % | Dividendenbekanntmachungen (09.10.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGNC INVESTMENT CORP US00123Q1040 0,12 USD EUR ALERUS FINANCIAL CORPORATION US01446U1034 0,22 USD EUR ALTRIA GROUP INC US02209S1033 1... ► Artikel lesen | |
| HANGZHOU TIGERMED CONSULTING | 4,280 | -1,38 % | TIGERMED (03347): 2026 THIRD QUARTERLY REPORT | ||
| AESTHETIC MEDICAL INTERNATIONAL | 0,009 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -3- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameKYG200801002 CBAK... ► Artikel lesen | |
| HEARTFLOW | 59,12 | +0,03 % | Biotech Stocks At 52-Week Highs - Vaxcyte +31% On Phase 3 Results, InfuSystem, Illumina +7%, Charles River Laboratories +7%, HeartFlow +5% | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data.Vaxcyte Inc. (PCVX)Vaxcyte is... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 59,48 | 0,00 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen |
Das Unternehmen IMMUNOVIA AB kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +8,33 % bei einem Aktienkurs von 0,001 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.